Evolus, Inc. (NASDAQ:EOLS) Insider Rui Avelar Sells 27,904 Shares

Evolus, Inc. (NASDAQ:EOLS) insider Rui Avelar sold 27,904 shares of Evolus stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $370,007.04. Following the completion of the sale, the insider now owns 362,467 shares in the company, valued at approximately $4,806,312.42. This represents a 7.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Rui Avelar also recently made the following trade(s):

• On Monday, December 23rd, Rui Avelar sold 2,252 shares of Evolus stock. The shares were sold at an average price of $10.85, for a total transaction of $24,434.20.

Evolus Stock Down 1.6 %

NASDAQ EOLS opened at $13.25 on Friday. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The company’s 50 day simple moving average is $13.36 and its 200 day simple moving average is $13.91. Evolus, Inc. has a 12 month low of $9.25 and a 12 month high of $17.82. The company has a market capitalization of $842.53 million, a P/E ratio of -14.56 and a beta of 1.28.

Analysts Set New Price Targets

EOLS has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Evolus in a research report on Wednesday, March 5th. Barclays boosted their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Evolus in a research report on Wednesday, March 5th.

Institutional Trading of Evolus

Hedge funds and other institutional investors have recently made changes to their positions in the business. KBC Group NV bought a new stake in shares of Evolus in the 4th quarter worth approximately $49,000. IFP Advisors Inc raised its holdings in shares of Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock worth $52,000 after purchasing an additional 4,709 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Evolus in the 3rd quarter worth approximately $132,000. KLP Kapitalforvaltning AS bought a new stake in shares of Evolus in the 4th quarter worth approximately $106,000. Finally, Rafferty Asset Management LLC bought a new stake in shares of Evolus in the 4th quarter worth approximately $115,000. 90.69% of the stock is currently owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.